Stephen P. Bradley

Statistics

Publications

Citations

165

H-Index

Active since

1996

Affiliations

Mersana Therapeutics (United States)(Current)

Stephen P. Bradley is an author at Mersana Therapeutics (United States) specializing in drug delivery, antibody-drug conjugate therapy, and antibody-drug conjugates.

ORCID

Publications per year

1996–2023

Publications

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects

Peter J. Rix, Andrew Vick, Neil Attkins et al. · Clinical Pharmacokinetics · 2014 · 47 citations · Full text

Medicine, Pharmacology, Toxicology +9

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins et al. · Molecular Cancer Therapeutics · 2023 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas et al. · Cancer Research · 2020 · 25 citations

Pharmacy, Immunology, Oncology +16

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2021 · 24 citations

Pharmacy, Oncology, Pharmacology +17

Right ventricular pathology in chronic pulmonary hypertension

Stephen P. Bradley, William R. Auger, Kenneth Μ. Moser et al. · The American Journal of Cardiology · 1996 · 20 citations

Medicine, Cardiology, Internal Medicine +12

1–5 of 6